We assessed the outcomes of high intensity focused ultrasound as primary treatment of localized prostate cancer in a retrospective series. This represents one of the largest published series of patients at intermediate and high risk. Materials and Methods: We performed a retrospective multicenter analysis of patients who underwent partial gland ablation between January 2013 and September 2017. Patients with biopsy proven localized disease and limited multifocality based on magnetic resonance imaging who preferred minimally invasive outpatient therapy were treated with the SonablateÒ 500 system. Oncologic and functional outcomes were analyzed as well as risk factors for recurrence. Results: A total of 166 procedures were performed in 150 patients. Grade Group 2 or greater was present in 89% of cases. Mean AE SD followup was 24.3 AE 14.4 months. Mean prostate specific antigen decreased 65% from 7.9 AE 6.8 ng/ml to a nadir of 2.7 AE 3.1 ng/ml. Confirmatory biopsies were performed in 87 patients (52%) at high risk for recurrence. Clinically significant cancer (Grade Group 2 or greater) was detected in 37 cases (42%). Patients with a higher number of positive cores, a medial tumor location or higher prostate specific antigen had a higher probability of recurrence. Salvage treatment was done in 37 patients (24.6%), including 16 repeat partial gland ablation procedures. Conclusions: Partial gland ablation with high intensity focused ultrasound therapy was safe and it had a minimal impact on functional outcomes. Local recurrence and/or failure occurred in 42% of patients at high risk for recurrence. Medially located tumors were associated with a higher failure rate. Serious complications were rare. Whole gland treatment was avoided in 81% of patients.
MAGNETIC resonance imaging targeted prostate biopsies have improved the accuracy of diagnosing clinically significant disease. 1e4 The index lesion concept 5 led to the appealing hypothesis that PGA would provide oncologic control while avoiding the side effects of definitive whole organ treatment. 6, 7 Recently focal HIFU, which aims to treat the index lesion in patients with a solitary focus of significant cancer, became an alternative to whole gland ablation. 8, 9 We report the short-term and intermediate term outcomes of PGA HIFU treatment.
MATERIALS AND METHODS
Patients at 3 medical centers who underwent primary PGA HIFU from January 2013 to September 2017 at the Can-Am HIFU clinic in Toronto, Ontario, Canada were included in study. Inclusion criteria were age greater than 18 years, clinical stage T1c-T2c biopsy proven prostate cancer, including extensive GG 1 (multiple positive cores with more than 50% core involvement) or GG 2 or greater disease, limited multifocality (up to 3 regions of interest amenable to focal or hemiablation) on mpMRI and the preference for a minimally invasive, nonradical approach instead of established treatments such as radical prostatectomy and XRT.
Procedures were done with the SonablateÒ 500 system. Most patients received focal or hemiablation and a few were treated with a hockey stick template covering up to 75% of the gland. This study was deemed exempt from International Review Board review.
Study Eligibility
Eligible patients had unilateral cT1-T2b prostate cancer which was thought to be clinically significant. Patients with bilateral significant cancer, cT3 disease or greater, cN1 or Mþ disease were excluded from analysis.
Treatment Description
Cases were staged by biopsy and 3 Tesla mpMRI with an abdominal array coil prior to the procedure. In the first 2 years of the study MRI was not widely available and 19% of included patients did not undergo a baseline MRI. These patients had unilateral significant cancer and negative contralateral biopsies. After MRI became more widely available, all patients underwent pretreatment MRI.
All procedures were performed with the patient under spinal anesthesia and intravenous sedation. A Foley catheter was placed to enhance probe positioning and identify the urethra. Co-registration with the MRI target was performed cognitively. All known clinically significant cancer was treated. The intent was to treat 5 to 10 times the lesion volume as identified on MRI. Treatment was performed according to a previously described HIFU technique. A safety margin of 3 mm was left at the apex. In select cases of apical cancer unilateral therapy was administered to the margin of the apex.
Followup
DRE and PSA measurements were made every 3 months in year 1 and every 6 months thereafter. Prostate biopsies were offered to patients 1 year after treatment. Patient resistance to compliance with followup biopsy was common in the absence of rising PSA or an indication of residual disease on MRI. Oncologic and functional outcomes were collected and analyzed retrospectively.
Statistical Analysis
All patient data were collected in an ExcelÒ spreadsheet. Continuous variables are expressed as the mean AE SD. Binary and categorical variables are reported as the count and percent. We used univariate and multivariable Cox proportional hazard models to search for significant predictive factors of RFS in PGA HIFU procedures. RFS time was calculated in months from the date of HIFU to the date of biopsy in patients with recurrence or to the last followup date if there was no recurrence. Recurrence was defined as GG 2 or higher on followup biopsy.
A Kaplan-Meier RFS curve was generated for all PGA HIFU procedures. Natural log transformation was applied for some covariates to normalize the distribution. The HR and the HR 95% CI were calculated for each covariate. All variables at p <0.10 obtained from univariate analysis were included in the backward selection procedure to account for all potential predictive factors. In the final multivariable model only variables at p <0.05 remained.
All analyses were done with SASÒ, version 9.4 for WindowsÒ and R, version 3.5.0 (https://www.r-project. org/). Statistical significance was considered at p <0.05.
RESULTS
A total of 150 patients underwent PGA HIFU of localized prostate cancer as primary definitive treatment between January 2013 and September 2017. Mean patient age at therapy was 64.9 AE 7.5 years and median baseline PSA was 6.8 ng/ml (IQR 4.4e9.1). GG 2 or greater disease was present in 145 cases (89%). Table 1 lists demographics and preoperative data. A total of 134 patients (81%) underwent mpMRI prior to PGA HIFU or diagnostic biopsy, which included MRI targeted biopsies in 57 (34%) (table 2). In 28% of cases the tumor location could not be identified retrospectively. Table 3 lists baseline functional characteristics.
To assess the treatment extent the prostate was divided into 12 zones, including the anterior and posterior base, the anterior and posterior mid gland and the anterior and posterior apex for each lobe. A total of 166 PGA HIFU procedures were performed in 150 patients. Despite the small volume of cancer (mean 1 cc) the treatment volume was approximately a third of the prostate volume. A mean of 4.8 AE 1.4 zones were treated. Of the procedures 58 (31.9%) were unilateral hemiablation.
Mean followup was 24.3 AE 14.4 months. Mean PSA decreased 65.1% from 7.9 AE 6.8 ng/ml before treatment to a nadir of 2.7 AE 3.1 ng/ml. The mean time from PGA HIFU to PSA nadir was 7.3 AE 6.2 months. Mean PSA at last followup was 4.2 AE 4.0 ng/ml, which was a mean 47% PSA decrease compared to baseline.
Followup MRI data were available on 114 patients. Mean time from the procedure to followup MRI was 12.1 AE 9 months. A positive MRI scan, defined as a PI-RADSÔ (Prostate Imaging Reporting and Data System) score of 3 or greater, was identified in 64 patients (56.1%). Lesions with a PI-RADS score of 3, 4 and 5 were noted in 16 (25%), 28 (43.7%) and 20 patients (31.3%), respectively.
Of the 166 PGA HIFU procedures 87 (52.4%) were followed by confirmatory biopsy with a mean of 14.8 AE 7.6 months from treatment to biopsy. MRI targeted biopsies were performed in 36.9% of cases. Of the 87 confirmatory biopsies performed clinically significant cancer, defined as GG greater than 1, was found in 37 cases (42.5%). The positive biopsy was found in the treated area in 19 cases (51.3%). Of the 114 patients who underwent followup MRI 50 (43.8%) had negative MRI results, of whom 22 underwent biopsy. Only 4 of those patients (8%) had clinically significant disease (table 4 and supplementary table 1 , http://jurology.com/).
In the MRI negative/no biopsy cohort of 25 men mean PSA at the last followup visit was 2.3 ng/ml. In this subgroup the mean nadir PSA was 1.4 ng/ ml. In contrast, in the MRI negative, biopsy positive cohort of 14 patients mean PSA at the last visit was 4.6 ng/ml and the mean PSA nadir was 3.0 ng/ml. Overall favorable oncologic outcomes were achieved in 97 of the 144 patients (67.4%) in whom followup was based on regular digital rectal examination, PSA measurement, and/or MRI and/or confirmatory biopsy. Actuarial median RFS was 16 months (95% CI 14e36) (fig 1) .
We constructed a univariate Cox proportional hazard model (supplementary table 2, http://jurology.com/). Nine predictive variables were significantly related to RFS. Patients with more positive cores, bilateral, a mid gland or medial tumor location, larger lesions, or a higher PSA nadir or latest value showed a higher probability of recurrence. Those with lateral tumor locations had a lower probability of recurrence compared to those with medial locations. On multivariable analysis the procedures with more positive cores (HR 1.46, p ¼ 0.010), a medial tumor location (HR 2.68, p ¼ 0.043) or higher PSA (HR 2.51, p ¼ 0.002) demonstrated a probability of recurrence (supplementary table 3 , http://jurology.com/, and fig. 2 ).
Salvage Treatment
Of the 150 patients who underwent PGA HIFU 37 (24.6%) proceeded through salvage treatment, including repeat PGA HIFU in 16, salvage XRT in 6, salvage ADT in 2 and salvage RP in 12. Of the 16 patients who underwent repeat PGA HIFU due to residual or recurrent disease 9 (56%) had GG 2 prostate cancer on confirmatory biopsy after the At a median followup of 9.6 months (range 3 to 27) full continence was achieved in 7 of the 12 patients (58%) while 5 more recent patients still needed 1 pad per day. Mean PSA in the salvage XRT/ADT cohort was 0.8 ng/ml at the last visit. Patients in the salvage RP and XRT/ADT subgroups showed a durable response to salvage therapy with no evidence of disease progression, although this was at short-term followup. Overall whole gland treatment was avoided in 111 of the 137 patients who were receiving regular followup (81%).
Functional Outcomes
During followup no change in continence, LUTS and erectile dysfunction was reported by 94.9%, 84.1% and 86.5% of patients, respectively. Six men (4.3%) reported improved LUTS after treatment (supplementary table 4, http://jurology.com/).
Safety and Side Effects
No intraoperative complications were reported. Data on treatment side effects were available for 153 of the 166 PGA HIFU procedures. A total of 51 adverse events (33.3%) were documented in 39 patients. Grade I complications based on the ClavienDindo classification were reported in 35 cases (22.9%) after PGA HIFU. The most common grade I complication was acute urinary retention in 20 patients (13.1%) (supplementary table 5, http://jurology.com/). A total of 12 patients (7.8%) experienced grade II complications and 4 (2.6%) underwent surgical intervention and were classified with a grade III complication.
In 4 men (2.6%) a urethrorectal fistula developed after PGA HIFU therapy. Mean time to fistula development was 5.5 AE 1.9 weeks. All patients were treated successfully with an indwelling Foley catheter for a mean of 5.5 weeks (range 3 to 8). No patient with a fistula required surgical intervention. Three patients were in year 1 of therapy. The remaining patient was receiving salvage treatment. The PGA therapy technique was altered after this initial experience to increase the cooling time between treatment pulses in the mid zone. Since making that technical alteration, no further fistulas have developed.
DISCUSSION
PGA HIFU therapy, which addresses the gap between active surveillance and whole gland therapy, usually focuses on patients with intermediate risk, clinically localized prostate cancer and aims to achieve a higher rate of the trifecta (cancer control, erectile function preservation and continence) as traditional therapy.
10e13 In this study 89% of patients had GG 2 or greater disease. This distinguishes our series from most known PGA HIFU published studies, in which the proportion of patients with Gleason score 6 has ranged from 32% to 86.6%. 7,14e20 We support routine post-HIFU biopsy. While routine posttreatment biopsy was promoted, patients with an excellent biochemical response with MRI indicating complete resolution of cancer tended to resist undergoing this biopsy. Thus, patients who underwent posttreatment biopsy in our study were curve of matching the extent of therapy to the extent of disease and other parameters which are difficult to quantify.
Significant cancer outside the treatment zone was found in 16 patients (11%). This may reflect the identification of cancer which was not identified on pretreatment MRI or else disease progression in the untreated prostate.
Of the patients 80% were at intermediate risk (GG 2 or 3), 12 (8%) had GG 4 disease and 1 had GG 5 disease. Although they were at high risk, these patients had a small volume of high grade disease on biopsy and solitary lesions less than 1.5 cm on MRI. They actively sought minimally invasive intervention and were aware that this approach was less likely to be successful than surgery or radiation. We acknowledge that PGA carries a significant risk of under treatment in these men at high risk.
The positive surgical margin rate was 25% in our salvage prostatectomy series. This is comparable to the 15% overall positive surgical margin rate of primary surgery and specifically in pT3 stage cases it was reported to be up to 37%. 21 Patients in the salvage RP and XRT/ADT subgroups showed a durable response to salvage therapy with no evidence of disease progression or spread.
LUTS and erectile dysfunction rates were reportedly unchanged after PGA HIFU in 84% and 86% of patients, respectively. These values compare favorably to patient reported outcomes after surgery or radiation.
The rate of adverse effects and complications was substantially lower than that associated with whole gland HIFU. 10, 11, 13 In our series most complications were Clavien-Dindo grade I. Only 2.6% of patients required surgical intervention. Our main concern was related to the development of urethrorectal fistulas in year 1 of PGA HIFU implementation. Four patients (2.6%) experienced a transient prostate rectal fistula related to the early technique. All patients responded successfully to catheter drainage. Since changing the technique to decrease the temporal intensity of treatment, no fistulas have developed.
There are a number of limitations to the current study. It was a retrospective study with no control arm and limited followup. Low patient motivation to comply with followup biopsy was common in those with dramatic PSA response and/or negative MRI. Of the patients 19% did not undergo pretreatment MRI, reflecting limited access to prostate MRI in Canada during the first few years that this treatment was offered. The cohort was heterogeneous in terms of the initial diagnostic strategy and followup.
CONCLUSIONS
PGA HIFU for localized prostate cancer is safe with a minimal long-term effect on quality of life. Persistent, clinically significant cancer was identified on biopsy in 42% of patients, of whom most had clinical features associated with a higher risk of recurrence. Failure was more common in cases of medial lesions, likely due to urethral sparing strategies. Whole gland treatment was avoided in 81% of patients. Complications beyond Clavien-Dindo grade 2 were rare.
